A novel C3G isoform, designated p87C3G, lacking the most amino terminal region of the cognate protein has been found to be overexpressed in two CML cell lines, K562
Introduction
C3G is a Crk-binding protein that shows transformation suppressor activity towards several oncogenes through a GEF-independent mechanism [1, 2] involving inhibition of ERK1/2 phosphorylation and cyclin A expression and resulting in lost of anchorage independent growth [1, 2] .
However, C3G also participates in proliferative pathways through the activation of Rap1 [3, 4] , and has been described as an essential gene in embryonic development [5] and integrin-mediated cellular adhesion and migration [5] [6] [7] [8] .
Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem cells caused by the Philadelphia chromosome (Ph) translocation [9] , which results in the generation of the Bcr-Abl fusion oncogene [10] . The N-terminal segment of Abl includes a SH3 domain which regulates the tyrosine kinase function of Abl. The fusion of Abl to Bcr interferes with the SH3 domain regulatory function causing the Bcr-Abl kinase to become constitutively active [11] .
C3G gene localizes to 9q34.3 and is telomeric to the c-abl locus (9q34.1), whose gene product is also a Crk-binding protein. In cells derived from CML, CrkL is constitutively phosphorylated and is one of the main substrates of Bcr-Abl tyrosine kinase [12] . In most cell types C3G is constitutively associated to CrkL, but in cells expressing Bcr-Abl this association decreases significantly probably due to the fact that both proteins bind CrkL in a mutually exclusive manner [6] . C3G is phosphorylated on Tyr-504 when coexpressed with Crk [13] and also C3G is phosphorylated upon integrin-mediated cell adhesion [6] . Moreover, it has been recently described that the Src family tyrosine kinase Hck, which activity is upregulated in Bcr-Abl expressing cells [14, 15] , phosphorylate C3G in hematopoietic cells, where both proteins play a role in apoptosis [16] .
Here we describe a novel C3G isoform, p87C3G, highly overexpressed in two hematopoietic cell lines related to CML, K562 and Boff 210, as well as in primary cells from CML patients at the time of diagnosis. p87C3G, lacks the N-terminal region and the first stretch of polyprolines of the SH3-binding (SH3-b) domain and is much more abundant than the full length p140C3G form in these cells. p87C3G, interacts with both CrkL and Bcr-Abl through its SH3-b domain and is phosphorylated in a Bcr-Abldependent manner, possibly involving Hck. These observations raise interesting possibilities for the putative participation of p87C3G in the pathogenesis of CML.
Materials and methods

Cell lines and tissue samples
K562, a human cell line derived from a patient with chronic myelogenous leukemia in terminal blast crisis was obtained from the ATCC (CCL 243) and maintained in RPMI 1640 (Life Technologies) containing 10% fetal bovine serum (FBS). Boff 210 is an interleukine 3-(IL3) independent cell line derived from the hematopoietic cell line BaF/3 [17] that expressed Bcr-Abl as a tetracycline-regulated transgene (Bcr-Abl expression is constitutive in absence of tetracycline or doxycycline). Boff 210 was maintained in DMEM (Life Technologies) supplemented with 10% FBS.
Mononuclear cells were obtained from blood samples of healthy individuals and CML patients in chronic phase (i) before treatment (more than 90% Ph+), (ii) treated with STI571 for two weeks (~50% Ph+) or (iii) with complete cytogenetic response after 6 months treatment with STI571 (0% Ph+) by lysing the red cells in a buffer containing 0.13 mM EDTA, 10 mM HKCO 3 
Antibodies and immunological studies
We have used the following antibodies: anti-C3G (c-19), anti-C3G (H-300), anti-c- 
Immunoprecipitations and In vitro phosphorylation
Immunoprecipitations and in vitro Kinase assays were performed as described [16] .
For the in vitro kinase assays either, 20 µCi [γ 32 P] ATP or 10 µM cold ATP were used.
The samples were resolved by SDS-PAGE and exposed to autoradiography or revealed with anti-phospho-tyrosine (p-Tyr) antibodies. 
Constructs in pGEX vectors
Bacterial expression of GST fusion proteins
Constructs pGST-CAT, pGST-C3G12 [1] , pGST-SH3-b, pGST-p87, pGST-P2 and pGST-SH3Abl were expressed in BL21 pLys strain of Escherichia coli and the corresponding GST-fusion proteins purified using the glutathione-agarose affinity method as described [18] . pGST-RalGDS-RBD (GST fused to the Ras binding domain of RalGDS, amino acid residues 701-851), was obtained from Dr. P. Crespo (University of Cantabria/Instituto de Investigaciones Biomédicas, Santander, Cantabria, Spain).
Rap1 activity assay
Boff 210 cells were growth to 1.5 x 10 5 cells/ml and serum starved for 20-24 h followed by incubation with EGF (epidermal growth factor) or IFN-α (interferon-α). 
Pull down experiments
Pull downs from cell extracts were carried out by incubating 1 mg of protein extract in lysis buffer with 0.1 to 2 µg of GST-fusion proteins, bound to glutathione-sepharose beads, for 2 hours at 4 o C. Complexes were subjected to 3 washes in lysis buffer and boiled in loading buffer before SDS-PAGE.
In vitro mutagenesis
Plasmid pGST-p87, containing whole p87C3G clone, was subjected to in vitro The PCR reactions were carried on at 95º, 30s; 55º 1 min; 68º, 11 min for 12 cycles and the mutations verified by automatic sequencing.
Results
Detection of a novel C3G isoform in K562 and Boff 210 cells
Type I and type II interferons, often used as a treatment for CML, activate CrkLRap1 signaling pathway in hematopoietic cells, presumably through the activation of C3G [19, 20] . To further study the involvement of C3G in this pathway, our first goal was to determine the expression of C3G in two models of CML, human K562 cells and form. Similarly, p87C3G is highly overexpressed in samples from CML patients at time of diagnosis as compared to healthy individuals ( Figure 1D ). This CML-associated p87C3G expression returns to basal levels after treatment with STI571 ( Figure 1D ).
The authenticity of this band was confirmed by specific blockage with the corresponding blocking peptide, which completely competed both p140C3G and p87C3G bands ( Figure 1B ,C right panel, Figure 1D middle panel). Furthermore, the p87C3G band is not recognized by an anti-C3G antibody against the 300 first amino acids of the protein (C3G H-300), which indicates that p87C3G conserves the Cterminus of full length C3G but it is truncated at its N-terminus ( Figure 1E ).
Cloning of the 5´end of p87C3G by RACE: estimation of p87C3G start point
The above results with anti-C3G (H-300) and anti-C3G (c-19) antibodies suggest that p87C3G lacks, at least, the first 300 amino acids of the entire C3G protein, while it contains an intact C-terminus. To determine the start point of this isoform, we performed 5´RACE analysis using total RNA from Boff 210 cells and two sets of three adjacent oligonucleotides, mC3G-C1, 2, 3 and mC3G-N1, 2, 3 oligos (Figure 2A ).
We C3G protein, as it is ubiquitously detected [1, 21] . The shorter, 4.4 kb transcript has been previously described in adult human heart and skeletal muscle where, in concordance, a 80-90 kDa transcript was also detected [1] . The presence of two transcripts in Boff 210 is in agreement with the detection of the two C3G isoforms (p140 and p87) in these cells.
All these results suggest that p87C3G isoform is not originated from full length C3G
by proteolytic digestion but it is translated from a spliced C3G mRNA.
Interaction of p87C3G with CrkL and Bcr-Abl
Immunoblotting of CrkL immunoprecipitates with anti-C3G (c-19) antibody revealed that p87C3G interacts with CrkL in K562 and Boff 210 cells ( Figure 4A ). Under our experimental conditions, we were unable to detect this interaction with full length p140C3G. The interaction between p87C3G and CrkL increased in cells treated with EGF, a known activator of the CrkL-Rap1 pathway [22] and when the expression of between Bcr-Abl and C3G in their binding to CrkL [6] .
Next, we studied whether p87C3G was also able to interact with Bcr-Abl in K562
and 
p87C3G interacts with Bcr-Abl through its SH3-binding domain
To characterize the p87C3G region involved in the interaction with Bcr-Abl, we performed pull down experiments of K562 lysates with several constructs of C3G fused to GST ( Figure 2B ). Figure 5A shows that only pGST-C3G12 and pGST-p87, containing, respectively, most of p87C3G and putative full length p87C3G, were able to pull down Bcr-Abl under these conditions, whereas constructs containing only the catalytic domain (GST-CAT) or the SH3-binding domain complete or partial (GST-SH3-b and GST-P2), failed to do so. As expected, constructs containing the SH3-binding domain complete or partial (but not the catalytic domain) were also able to interact with CrkL.
Bcr-Abl protein contains a SH3 domain that could potentially interact with the SH3-binding domain of C3G. To test this hypothesis we cloned the SH3 domain of Bcr-Abl fused to GST and performed pull down assays in K562 lysates with the resulting construct pGST-SH3Abl. Figure 5B shows that the SH3 domain of Bcr-Abl interacts with both p87C3G and CrkL. This interaction is specific of the SH3 domain of Bcr-Abl, since GST alone did not interact with p87C3G or with CrkL.
Contribution of the P2 region of the C3G SH3-binding domain is essential for its interaction with Bcr-Abl
To further confirm the specificity of the interaction between p87C3G and BcrAbl, we performed in vitro mutagenesis of the C3G SH3-binding domain, using pGSTp87 construct. We designed three different mutants of the C3G SH3-binding region, each one mutated in a different polyproline region (P2, P3 and P4, Figure 2B ) with all the Prolines substituted by Glycines. Pull down experiments with these mutants (mP2, mP3 and mP4) showed that only mutations in the P2 region of the C3G SH3-binding domain significantly decrease the interaction between p87C3G and Bcr-Abl ( Figure   5C ), suggesting that this region is the most important in the interaction between p87C3G and Bcr-Abl. Mutations in this polyproline stretch did not significantly affect to the interaction with CrkL ( Figure 5C ).
p87C3G is phosphorylated through a Bcr-Abl kinase-dependent mechanism
C3G is phosphorylated on Tyr-504 upon integrin-mediated cell adhesion [6] or coexpression with CrkI [13] . Recently the Src family tyrosine kinase Hck, which is specifically activated by Bcr-Abl in hematopoietic cells [14] , was described to phosphorylate C3G in this cell type, where both proteins play a role in apoptosis [16] . Figure 6D ). Both p140C3G and p87C3G were found phosphorylated in the C3G immunoprecipitates, indicating that C3G interacts and is a substrate for cellular kinase activities ( Figure 6B ).
Besides, p87C3G was also tyrosine phosphorylated in the Abl immunocomplexes, presumably through the kinase activity of Bcr-Abl, as this phosphorylation decreases in cells treated with STI571, a known inhibitor of the Bcr-Abl kinase function, ( Figure 6C and Figure 6D , upper panel). In agreement with previous reports [16] , p87C3G was also found tyrosine phosphorylated in Hck immunoprecipitates being this phosphorylation also dependent on Bcr-Abl kinase ( Figure 6D ). The presence and phosphorylation of p87C3G and Hck in the immunoprecipitates are specific as these proteins are absent in control cell lysate incubated with beads (data not shown). Thus, the phosphorylation of p87C3G seems to occur in a complex with Bcr-Abl and Hck and is, at least in part, dependent on Bcr-Abl activity.
Discussion
In this paper, we described the detection and characterization of a novel C3G
isoform, p87C3G, which may play a putative role in the pathogenesis of CML since its expression is significantly increased in untreated CML patients, as compared to normal healthy donors or patients treated with STI571, and interacts with the Bcr-Abl oncogene responsible of the malignant transformation of CML cells. p87C3G is also detected in unrelated tissues, like NIH 3T3 fibroblasts, although at very low levels compared to CML cell lines (data not shown). In addition to the ubiquitous 7.5 kb transcript, corresponding to full length C3G, a second transcript of about 4.4 kb was detected in
Boff 210 RNA, in agreement with the presence of p87C3G in these cells. A shorter transcript of similar size, containing the 3´end of C3G but lacking the 5´end, was also previously described in tissues such as human heart and skeletal muscle where, in accordance, a band of 80-90 kDa was also present at the protein level [1] .
Under our experimental conditions, we have been unable to detect interaction between Bcr-Abl and full length C3G, probably due to its low expression in CML cells.
A recent article by Cho et al, showed p140C3G/Bcr-Abl interaction, although it has to be mention that the authors only detected this interaction in COS cells transfected with the corresponding DNAs but not in K562 cells of in MEFs from Bcr-Abl p190 transgenic mice [23] . Also results by these authors suggesting cooperation between Rap1 pathway and Bcr-Abl are in disagreement with our results where Rap1 is highly activated when Bcr-Abl expression decreases by the presence of doxycycline ( Figure   4B ). The antagonism between the CrkL-Rap1 and the Bcr-Abl pathways has been reported by other authors demonstrating that, in fact, the CrkL-Rap1 pathway exhibits suppressive effects on Bcr-Abl expressing cells [20, 24, 25] .
Using rapid amplification of 5´cDNA ends (RACE) technique, we identified the putative start codon of p87C3G at positions 321 and 306 of mouse and human C3G
proteins respectively, located after the first Proline-rich stretch. RACE allowed us to generate fragments upon 1 kb in length when using oligonucleotides from the 3´end of C3G gene (C-T oligos). The fact that all the N-T fragments obtained were smaller than 500 bp strongly suggests these fragments nearly reached the 5´ end of the corresponding mRNA. Nevertheless, it is surprising that we could not obtain larger fragments with the N-T oligonucleotides, considering that both mRNA species (full length p140C3G and p87C3G) must coexist in the cell. A plausible explanation is that p87C3G is much more abundant and/or more stable than full length C3G in these cells, thus favouring the amplification of p87C3G RNA in the RACE reaction. We consider that Fluorescence in situ chromosomal hybridization (FISH) revealed that there is a single chromosomal loci for C3G gene at 9q34.3 [26] , strongly suggesting that the p87C3G isoform arises from alternative splicing of a unique transcript. Besides, Shrivakrupa et al. cloned a C3G fragment (C9) from a rat spleen cDNA library that also started just after the first Proline-rich stretch, similarly to our p87C3G clone [27] , further supporting the idea of p87C3G being an alternative spliced form of C3G.
Both p87C3G and C3G12 (lacking the first 86 amino acids of p87C3G) interact with
CrkL and Bcr-Abl. These interactions were specific of the mentioned fragments, as the catalytic region alone did not interact either with CrkL (as expected) or with Bcr-Abl.
Small fragments containing (totally or partially) just the SH3-binding region failed to pull down Bcr-Abl, whereas they interacted with CrkL. It is possible that the interaction Bcr-Abl/p87C3G involves only the SH3-b domain of p87C3G although the rest of the p87C3G protein is necessary for the stability of the binding.
In addition, our data indicate that at least the SH3 domain of Abl is involved in the interaction between Bcr-Abl and p87C3G. A previous report established that the C3G SH3-binding domain only interacts with CrkL and, weakly, with Grb2 N-SH3 domain but not with Abl SH3 domain [28] , although It should be mentioned that these experiments were performed in vitro and in HeLa cells. Surprisingly, the SH3 domain of Bcr-Abl also interacts with CrkL. This would constitute an additional interaction site between these two molecules, since it is known that Bcr-Abl also interacts with CrkL through the SH3-binding domain of Bcr-Abl and the N-T SH3 domain of CrkL [12, 29] .
There is evidence for a potential SH3-binding domain inside the SH2 domain of CrkL that may explain this interaction [30] .
In vitro mutagenesis experiments demonstrated that the second Proline-rich domain (P2) of C3G (i.e. the first polyproline stretch in p87C3G) is the most critical in the interaction with Bcr-Abl and confirm the specificity of such interaction as mutations in this domain only affect to the interaction of p87C3G with Bcr-Abl but not to the interaction with CrkL ( Figure 5C ).
Kinase studies performed in Figure 6 revealed that (i) p87C3G is found tyrosine phosphorylated in Boff210 and K562 cells, (ii) C3G proteins coimmunoprecipitate with a tyrosine kinase activity, (iii) only p87C3G, but not p140C3G (at least under the experimental conditions used) is phosphorylated in vitro in a Bcr-Abl-dependent manner, and (iv) p87C3G is also phosphorylated in Hck immunocomplexes by a BcrAbl kinase-dependent mechanism. Thus, the phosphorylation of p87C3G seems to occur in a complex with Bcr-Abl and Hck and is dependent, at least partially, on BcrAbl activity since addition of STI571 to the reaction decreases p87C3G phosphorylation. We also found Hck to be tyrosine phosphorylated in both C3G and Hck immunocomplexes, being this phosphorylation independent on Bcr-Abl catalytic activity, in agreement with a previous report [15] . Nevertheless, contrarily to those authors, we were unable to detect Hck in Abl immunocomplexes ( Figure 6D , lower panel). One interesting point is that, although p87C3G phosphorylation seems to be mediated by Bcr-Abl catalytic activity, the interaction between Bcr-Abl and p87C3G is independent on Bcr-Abl kinase as it does not vary in the presence of STI571 ( Figure   6D , lower panel).
On the other hand, data in Figure 6A also indicate that p87C3G is constitutively phosphorylated on tyrosine residues in K562 and Boff 210 cells and that decreasing of CrkL and Crk [6, 31] and suggest that C3G is involved in p210 Bcr-Abl signaling.
Nevertheless, these results are in apparent contradiction with the kinase assay results
( Figures 6B-D) showing a dependence of p87C3G phosphorylation on Bcr-Abl kinase function. One possible explanation is that several pathways phosphorylating C3G coexist in hematopoietic cells. Thus, in Figure 6B -C we are detecting only p87C3G directly phosphorylated by kinase activities that form complexes with C3G, presumably
Bcr-Abl and Hck, while in Figure 6A we are detecting all phosphorylated p87C3G in the cell. It is well known that C3G phosphorylation is modulated by cell adhesion and that this property is altered in CML cells. In fact, CML cells express an adhesioninhibitory variant of β1 integrin that is not found in normal progenitors [10] . In the presence of Dx, when Bcr-Abl expression is decreased, there is an increase in p87C3G phosphorylation ( Figure 6A ), probably due to an increase in CrkL available to interact with p87C3G ( Figure 4A ) which results in an increase in Rap1 activation ( Figure 4B ).
In hematopoietic cells activation of Rap1 triggers an "inside out" signal that activates integrin-mediated cell adhesion [10, 32] . Reciprocally, it also possible that when the expression of Bcr-Abl decreases there is an increase in β integrins-mediated cell adhesion that can activates the CrkL-C3G-Rap1 pathway through an "outside in" signal [6, 8, 10, [32] [33] [34] .
Curiously, the SH3 domain of Bcr-Abl is the one involved in regulation of adhesion to laminin and collagens of leukemic cells through the formation of α 2 β 1 integrin complexes [35] , which is in agreement with a functional cooperation between p87C3G
and Bcr-Abl by its SH3 domain.
In conclusion, we have described a novel isoform of C3G (p87C3G) abundantly expressed in CML cells that, through its interaction with the SH3 regulatory domain of Bcr-Abl, may play a role in the pathogenesis of CML. Further studies will be necessary to investigate the significance of this novel connection between Bcr-Abl and p87C3G, and whether it is related to the adhesive properties of leukemic cells. 
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